• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
Health

Israeli health ministry says Pfizer vaccine prevents severe sickness—but not infection

By
Yaacov Benmeleh
Yaacov Benmeleh
and
Bloomberg
Bloomberg
Down Arrow Button Icon
By
Yaacov Benmeleh
Yaacov Benmeleh
and
Bloomberg
Bloomberg
Down Arrow Button Icon
July 23, 2021, 4:47 AM ET
Video Poster

Pfizer Inc.’s Covid-19 vaccine provided a strong shield against hospitalization and more severe disease in cases caused by the contagious delta variant in Israel in recent weeks, even though it was just 39% effective in preventing infections, according to the country’s health ministry.

The vaccine, developed with BioNTech SE, provided 88% protection against hospitalization and 91% against severe illness for an unspecified number of people studied between June 20 and July 17, according to a report Thursday from the health ministry.

The report said that the data could be skewed because of different ways of testing vaccinated groups of people versus those who hadn’t been inoculated. Still, the data are likely to fuel debate over whether booster shots should be given to people who’ve already been vaccinated — something Pfizer has said it plans to request in the U.S. Israeli authorities said earlier this month they’ll only give a third round of shots to people with weakened immune systems.

The data out of Israel, which had earlier access to vaccines than most anywhere else in the world, contrast with a study out of the U.K. That paper, published this week in the New England Journal of Medicine, found that two doses of the Pfizer-BioNTech vaccine offer 88% protection against symptomatic disease caused by the delta variant and 94% against the alpha variant that was first discovered in Britain. Public Health England also previously found that the Pfizer and BioNTech shot was 96% effective against hospitalization.

Pfizer and BioNTech are confident in the protection and safety of the two-dose vaccine, Pfizer said in a statement on Friday. BioNTech is conducting an ongoing review of study data on the vaccine, a spokeswoman said.

Analysis of the companies’ more than 43,000-person clinical trial shows that effectiveness against symptomatic infection dips over time, from 95% in the first two months to the low- to mid-80% range four to six months after the second dose, Pfizer said.

The delta variant first emerged in India and is spreading around the globe as governments race to inoculate people, sometimes infecting those already fully vaccinated against Covid. The mutation has forced some countries to delay or rethink plans to loosen curbs on businesses, activity and travel.

Israel has had one of the world’s most effective inoculation drives, with 57% of the population fully vaccinated, but has seen a recent surge in infections due to delta. Critical cases have also climbed, but remain a fraction of the peak earlier this year.

Prime Minister Naftali Bennett has urged vaccine holdouts — who number some 1.1 million people — to get inoculated, calling it the most effective way to defeat the delta strain. The government has also reinstated some restrictions for indoor events and plans to ban flights to several countries with rising infection rates, including the U.K. and Cyprus.

–With assistance from Naomi Kresge.

Subscribe to Fortune Daily to get essential business stories straight to your inbox each morning.

About the Authors
By Yaacov Benmeleh
See full bioRight Arrow Button Icon
By Bloomberg
See full bioRight Arrow Button Icon

Latest in Health

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025

Most Popular

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Fortune Secondary Logo
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Fortune Crypto
  • Features
  • Leadership
  • Health
  • Commentary
  • Success
  • Retail
  • Mpw
  • Tech
  • Lifestyle
  • CEO Initiative
  • Asia
  • Politics
  • Conferences
  • Europe
  • Newsletters
  • Personal Finance
  • Environment
  • Magazine
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
  • Group Subscriptions
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • Pinterest icon

Latest in Health

Healthmeal delivery
The 6 Best Gluten-Free Meal Delivery Services of 2026: Nutritionist Approved
By Emily PharesMarch 20, 2026
10 hours ago
Healthmeal delivery
Home Chef Meal Delivery Review (2026): Taste Tester Approved
By Christina SnyderMarch 20, 2026
10 hours ago
Healthmeal delivery
The 4 Best Frozen Meal Delivery Services (2026): Personally Taste Tested
By Christina SnyderMarch 20, 2026
14 hours ago
A podium with a sign reading "save healthcare" stands in front of the U.S. Capitol building.
Healthaffordability
‘Sometimes I don’t even take my medicine’: Americans are choosing between insulin and buying gas following Trump’s ACA cuts
By Ali Swenson and The Associated PressMarch 19, 2026
1 day ago
HealthDietary Supplements
The 4 Best Turmeric Supplements (2026): Expert Approved
By Emily PharesMarch 19, 2026
1 day ago
Legion as best vegan protein powder
HealthDietary Supplements
The 6 Best Vegan Protein Powders (2026): Plant-Based Options for Anyone
By Christina SnyderMarch 19, 2026
2 days ago

© 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.